The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Budzinskaia M.V.

FGBU "Nauchno-issledovatel'skiĭ institut glaznykh bolezneĭ" RAMN, Moskva

Mazurina N.K.

Posterior segment eye surgery and diagnostics center LLC, 2-aya Vladimirskaya St., Moscow, Russian Federation, 111123

Egorov A.E.

Pirogov Russian National Research Medical University, 1 Ostrovityanova St., Moscow, Russian Federation 117997

Kuroedov A.V.

Pirogov Russian National Research Medical University, 1 Ostrovityanova St., Moscow, Russian Federation 117997;
Mandryka Clinical Research and Training Medical Center, 8A Bol'shaya Olen'ya St., Moscow, Russian Federation, 107014

Loskutov I.A.

Scientific Clinical Center of JSC Russian Railways, 20 Chasovaya St., Russian Federation, 125315

Pliukhova A.A.

FGBU "NII glaznykh bolezneĭ" RAMN, Moskva

Razik S.

Medical diagnostic center «Olimp» LLC, 77 Udal’tsova St., Moscow, Russian Federation, 119454

Ryabtseva A.A.

Vladimirsky Moscow Regional Research Clinical Institute, Moscow

Simonova S.V.

S.P. Botkin State Clinical Hospital, Branch №1, Moscow Department of Public Health, 7 Mamonovskiy pereulok, Moscow, Russian Federation, 123001

Retinal vein occlusion management algorithm. Part 2. Macular edema

Authors:

Budzinskaia M.V., Mazurina N.K., Egorov A.E., Kuroedov A.V., Loskutov I.A., Pliukhova A.A., Razik S., Ryabtseva A.A., Simonova S.V.

More about the authors

Journal: Russian Annals of Ophthalmology. 2015;131(6): 57‑66

DOI: 10.17116/oftalma2015131657-66

Read: 2206 times

Download PDF (RU)
Contact the author
Table of contents

RETINAL VEIN OCCLUSION MANAGEMENT ALGORITHM. PART 2. MACULAR EDEMA
RETINAL VEIN OCCLUSION MANAGEMENT ALGORITHM. PART 2. MACULAR EDEMA

To cite this article:

Budzinskaia MV, Mazurina NK, Egorov AE, et al. . Retinal vein occlusion management algorithm. Part 2. Macular edema. Russian Annals of Ophthalmology. 2015;131(6):57‑66. (In Russ.)
https://doi.org/10.17116/oftalma2015131657-66

Подписка 2026 Вестник офтальмологии (Russian Annals of Ophthalmology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Biosimilars of rani­bizumab in reti­nal diseases: new possibilities in ophthalmology. Russian Annals of Ophthalmology. 2025;(2):106-116
Risk factors and adve­rse outcomes of cardiovascular diseases in people with high normal blood pressure of the Ryazan region. (5-year prospective follow-up). Russian Journal of Preventive Medi­cine. 2025;(2):31-37
Diagnostics of hype­rtensive diso­rders in cardio-obstetrics: current state-of-affairs. Russian Journal of Human Reproduction. 2025;(1):63-77
Study of the levo­carnitine effi­cacy for the treatment of mode­rate cognitive impairment in patients with hype­rtension. Russian Journal of Preventive Medi­cine. 2025;(4):45-50
Curcumin-induced increased reti­nal fluorescence as a new method in the early diagnosis of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):19-25
Clinical obse­rvation and complications in the treatment of a child with capi­llary malformation in the facial area. Stomatology. 2025;(4):98-102
Study of the effe­ctiveness of the drug Elca­rnitine in the correction of increased variability of arte­rial pressure in patients with hype­rtensive disease and cognitive dysfunction. Russian Journal of Preventive Medi­cine. 2025;(10):88-92
Abstract:

Macular edema (ME) is the most common complication of both ischemic and nonischemic retinal vein occlusion (RVO). If the main trunk of the central retinal vein is involved, ME occurs in 100% of cases. According to the Central Vein Occlusion Study, in 65% of RVO and ME patients with baseline visual acuity (VA) of at least 0.5 (Golovin-Sivtsev chart) or higher, ME may resolve itself without treatment with subsequent VA improvement. Therefore, we recommend a 3-month treatment-free follow-up of nonischemic central RVO (CRVO) and ME patients with VA of 0.5 or higher. If no improvement is noted within this period, treatment is initiated. Immediate treatment is required in patients with cystic ME revealed by optical coherence tomography (OCT) and VA below 0.5. Ischemic maculopathy is extremely unpromising. Modified grid laser photocoagulation should not be used as monotherapy for macular edema. Repeated corticosteroid (Ozurdex) and/or anti-VEGF (ranibizumab, aflibercept) intravitreal injections are considered the first choice treatment for ME in CRVO patients. Efficiency assessments should include monthly OCT. For persistent ME, intravitreal therapy can be supplemented by laser retinal photocoagulation (panretinal or modified grid). Anti-VEGF treatment schemes should be adjusted in BRVO patients as most of their edemas are self-limiting. Of laser photocoagulation techniques, only modified grid is used.

Keywords:

eye
retina
hypertension
central retinal vein occlusion
branch retinal vein occlusion
macular edema
laser photocoagulation
ranibizumab
Ozurdex
aflibercept

Authors:

Budzinskaia M.V.

FGBU "Nauchno-issledovatel'skiĭ institut glaznykh bolezneĭ" RAMN, Moskva

Mazurina N.K.

Posterior segment eye surgery and diagnostics center LLC, 2-aya Vladimirskaya St., Moscow, Russian Federation, 111123

Egorov A.E.

Pirogov Russian National Research Medical University, 1 Ostrovityanova St., Moscow, Russian Federation 117997

Kuroedov A.V.

Pirogov Russian National Research Medical University, 1 Ostrovityanova St., Moscow, Russian Federation 117997;
Mandryka Clinical Research and Training Medical Center, 8A Bol'shaya Olen'ya St., Moscow, Russian Federation, 107014

Loskutov I.A.

Scientific Clinical Center of JSC Russian Railways, 20 Chasovaya St., Russian Federation, 125315

Pliukhova A.A.

FGBU "NII glaznykh bolezneĭ" RAMN, Moskva

Razik S.

Medical diagnostic center «Olimp» LLC, 77 Udal’tsova St., Moscow, Russian Federation, 119454

Ryabtseva A.A.

Vladimirsky Moscow Regional Research Clinical Institute, Moscow

Simonova S.V.

S.P. Botkin State Clinical Hospital, Branch №1, Moscow Department of Public Health, 7 Mamonovskiy pereulok, Moscow, Russian Federation, 123001

Close metadata

References:

  1. Central Vein Occlusion Study Group. Baseline and early natural history report: the Central Vein Occlusion Study. Arch Ophthalmol. 1993;111:1087-1195. doi:10.1001/archopht.1993.01090080083022
  2. Branch Vein Occlusion Study Group: Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol. 1984;98:271-282. doi:10.1016/0002-9394(84)90316-7
  3. McIntosh RL, Rogers SL, Lim L et al. Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010;117:1113-1123. doi:10.1016/j.ophtha.2010.01.060
  4. Kiire CA, Chong NV. Managing retinal vein occlusion. BMJ. 2012;344:499. doi:10.1136/bmj.e499
  5. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number I. Arch Ophthalmol. 1985;103(12):1796-1806. doi:10.1001/archopht.1985.01050120030015
  6. Central Vein Occlusion Study Group. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. Ophthalmology. 1995;102(10):1425-1433. doi:10.1016/s0161-6420(95)30849-4
  7. Scott IU, Van Veldhuisen PC, Oden NL, Ip MS, Blodi BA, Jumper JM, Figueroa M, SCORE Study Investigator Group. SCORE Study report 1: baseline associations between central retinal thickness and visual acuity in patients with retinal vein occlusion. Ophthalmology. 2009;116(3):504-512. doi:10.1016/j.ophtha.2008.10.017
  8. Ip MS, Scott IU, Van Veldhuisen PC, Oden NL, Blodi BA, Fisher M, Singerman LJ, Tolentino M, Chan CK, Gonzalez VH, SCORE Study Research Group: A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care versus Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol. 2009;127(9):1101-1114. doi:10.1001/archophthalmol.2009.234
  9. Haller JA, Bandello F, Belfort R Jr, Blumen- kranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM. OZURDEX GENEVA Study Group: randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117(6):1134-1146. doi:10.1016/j.ophtha.2010.03.032
  10. Coscas G, Augustin A, Bandello F et al. Retreatment with Ozurdex for macular edema secondary to retinal vein occlusion. Eur J Ophthalmol. 2014;24(1):1-9. doi:10.5301/ejo.5000376
  11. Capone A, Singer MA, Dodwell DG, Dreyer RF, Oh KT, Roth DB, Walt JG, Scott LC, Hollander DA. Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (Shasta study). Retina. 2014;34(2):342-351. doi:10.1097/IAE.0b013e318297f842
  12. Capone A, Singer MA, Dodwell DG, Dreyer RF, Oh KT, Roth DB, Walt JG, Scott LC, Hollander DA. Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (Shasta study). Retina. 2014;34(2):342-351. doi:10.1097/IAE.0b013e318297f842
  13. Brown DM, Campochiaro PA, Singh RP et al. CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1124-1133. doi:10.1016/j.ophtha.2010.02.022
  14. Heier JS, Campochiaro PA, Yau L et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology. 2012;119(4):802-809. doi:10.1016/j.ophtha.2011.12.005
  15. Campochiaro PA, Raafay Sophie, Joel Pearlman, Brown DM, Boyer DS, Heier JS, Marcus DM, Leonard Feiner, Arun Patel, for the RETAIN Study Group. Long-term Outcomes in Patients with Retinal Vein Occlusion Treated with Ranibizumab. The RETAIN Study. Ophthalmology. 2014;12(1)1:209-219. doi:10.1016/j.ophtha.2013.08.038
  16. Campochiaro PA, Brown DM, Awh CC, Young Lee S, Sarah Gray, Namrata Saroj, Wendy Yee Murahashi, Rubio RG. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology. 2011;118(10):2041-2049. doi:10.1016/j.ophtha.2011.02.038
  17. David Boyer, Jeffrey Heier, Brown DM, Lloyd Clark W, Robert Vitti, Berliner AJ, Georg Groetzbach, Oliver Zeitz, Rupert Sandbrink, Xiaoping Zhu, Karola Beckmann, Haller JA. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology. 2012;119(5):1024-1032. doi:10.1016/j.ophtha.2012.01.042
  18. Brown DM, Heier JS, Lloyd Clark W, Boyer DS, Robert Vitti, Berliner AJ, Oliver Zeitz, Rupert Sandbrink, Xiaoping Zhu, Haller JA. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-Year Results From the Phase 3 COPERNICUS Study. American Journal of Ophthalmology. 2013;155(3):429-437. doi:10.1016/j.ajo.2012.09.026
  19. Holz FG, Roider J, Ogura Y, Korobelnik J-F, Simader C, Groetzbach G, Vitti R, A Berliner J, Hiemeyer F, Beckmann K, Zeitz O, Sandbrink R. VEGF trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. British Journal of Ophthalmology. 2013;97(3):278-284. doi:10.1136/bjophthalmol-2012-301504
  20. Jean-François Korobelnik, Holz FG, Johann Roider, Yuichiro Ogura, Christian Simader, Ursula Schmidt-Erfurth, Katrin Lorenz, Miki Honda, Robert Vitti, Berliner AJ, Florian Hiemeyer, Brigitte Stemper, Oliver Zeitz, Rupert Sandbrink, or the GALILEO Study Group. Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study. Ophthalmology. 2014;121(1):202-208. doi:10.1016/j.ophtha.2013.08.012
  21. Matus Rehak, Eric Tilgner, Annegret Franke, Rauscher FG, Oana Brosteanu, Peter Wiedemann. Early peripheral laser photocoagulation of nonperfused retina improves vision in patients with central retinal vein occlusion (Results of a proof of concept study). Graefe's Archive for Clinical and Experimental Ophthalmology. 2013;252(5):745-752. doi:10.1007/s00417-013-2528-8
  22. Spaide RF. Prospective study of peripheral panretinal photocoagulation of areas of nonperfusion in central retinal vein occlusion. Retina. 2013;33(1):56-62. doi:10.1097/iae.0b013e3182641875
  23. Shroff D, Mehta DK, Arora R, Narula R, Chauhan D: Natural history of macular status in recent-onset branch retinal vein occlusion: an optical coherence tomography study. International Ophthalmology. 2008;28(4):261-268. doi:10.1007/s10792-007-9123-0
  24. Rogers SL, McIntosh RL, Lim L, Mitchell P, Cheung N, Kowalski JW, Nguyen HP, Wang JJ, Wong TY. Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010;117(6):1094-1101. doi:10.1016/j.ophtha.2010.01.058
  25. Branch Vein Occlusion Study Group: Argon laser photocoagulation for macular edema in branch vein occlusion. American Journal of Ophthalmology. 1984;98(3):271-282. doi:10.1016/0002-9394(84)90316-7
  26. The SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol. 2009;127(9):1115-1128. doi:10.1001/archophthalmol.2009.233
  27. Mei Hong Tan, Mcallister IL, Gillies ME, Nitin Verma, Gayatri Banerjee, Smithies LA. Wan-Ling Wong, Wong TY. Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion. Am J Ophthalmol. 2014;157(1):237-247. doi:10.1016/j.ajo.2013.08.013
  28. Campochiaro PA, Lloyd Clark W, Boyer DS, Heier JS, Brown DM, Robert Vitti, Husain Kazmi, Alyson J. Berliner, Kristine Erickson, Chu KW, Yuhwen Soo, Yenchieh Cheng, Haller JA. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology. 2015;122(3):538-544. doi:10.1016/j.ophtha.2014.08.031
  29. Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Sarah Gray, Namrata Saroj, Adamis AP, Rubio RG, Wendy Yee Murahashi. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology. 2011;118(8):1594-1602. doi:10.1016/j.ophtha.2011.02.022
  30. Campochiaro PA, Heier JS, Feiner L et al., BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1102-1112. doi:10.1016/j.ophtha.2010.02.021
  31. Pielen A, Mirshahi A, Feltgen N, Lorenz K, Korb C, Junker B, Schaefer C, Zwiener I, Hattenbach LO. RABAMES Study Group. Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES): six-month results of a prospective randomized clinical trial. Acta Ophthalmol. 2015;93(1):29-37. doi:10.1111/aos.12488
  32. Novartis Pharmaceuticals 2014. Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion (BRIGHTER). http://clinicaltrials.gov/show/NCT01599650 (accessed 14 Nov 2014).
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.